Condition: Metastatic NSCLC - Non-Small Cell Lung Cancer · Sponsor: Necmettin Erbakan University
Large granular lymphocytes (LGLs), which constitute 10-15% of peripheral blood mononuclear cells, are large lymphocytes with a round nucleus, large cytoplasm, and azurophilic granules in the cytoplasm. Most normal LGLs in peripheral blood are natural killer (NK) cells, but some are T lymphocytes. These cells cannot be measured by a standard complete blood count (CBC) test. These cells, which can be detected by peripheral smear, are expressed numerically and as a percentage relative to other cells. The aim of this study is to determine the relationship between the percentage of LGLs at baseline and at three months and the response and clinical parameters in participants with metastatic non-small cell lung cancer treated with nivolumab in second-line therapy.
This description comes directly from the study's public registry record.
Ahmet Oruç MD · +90 0505 704 50 20 · mdahmetoruc@gmail.com
Mehmet Artaç MD · +90 532 267 98 38 · mehmetartac@yahoo.com
Always discuss trial participation with your own doctor first.
| Necmettin Erbakan University Faculty of Medicine, Department of Medical Oncology | Konya, Meram, Turkey (Türkiye) | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07363811